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Astrocytomas develop intense vascular proliferation, essential for tumour growth and invasiveness. Angiotensin II (ANGII) was initially
described as a vasoconstrictor; recent studies have shown its participation in cellular proliferation, vascularisation, and apoptosis. We
conducted a prospective study to evaluate the expression of ANGII receptors – AT1 and AT2 – and their relationship with
prognosis. We studied 133 tumours from patients with diagnosis of astrocytoma who underwent surgery from 1997 to 2002. AT1
and AT2 were expressed in 52 and 44% of the tumours, respectively, when determined by both reverse transcriptase–polymerase
chain reaction and immunohistochemistry. Ten per cent of low-grade astrocytomas were positive for AT1, whereas grade III and IV
astrocytomas were positive in 67% (Po0.001). AT2 receptors were positive in 17% of low-grade astrocytomas and in 53% of high-
grade astrocytomas (P¼0.01). AT1-positive tumours showed higher cellular proliferation and vascular density. Patients with
AT1-positive tumours had a lower survival rate than those with AT1-negative (Po0.001). No association to survival was found for
AT2 in the multivariate analysis. Expression of AT1 and AT2 is associated with high grade of malignancy, increased cellular
proliferation, and angiogenesis, and is thus related to poor prognosis. These findings suggest that ANGII receptors might be potential
therapeutic targets for high-grade astrocytomas.
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Glial tumours are the most frequent neoplasms of the central
nervous system; three-quarters of these are malignant, such as
anaplastic astrocytoma (AA) and glioblastoma multiforme (GM),
both associated with poor prognosis (Reardon et al, 2006). Despite
multidisciplinary therapeutic approaches, the median survival for
patients with GM is approximately 12 months after diagnosis
(Lopez-Gonzalez and Sotelo, 2000; Sotelo et al, 2006). High-grade
astrocytomas (AA and GM) display high cellular proliferation and
extensive angiogenesis (Tuettenberg et al, 2006) stimulated by the
production of growth factors such as platelet-derived growth factor
(PDGF), vascular endothelial growth factor (VEGF), and hepato-
cyte growth factor (Strugar et al, 1995; Moriyama et al, 1999;
Schmidt et al, 1999; Arrieta et al, 2002). Angiotensin II (ANGII) is
the main effector in the renin-angiotensin-aldosterone system
(RAAS) – a powerful vasoconstrictor system – (Matsusaka and
Ichikawa, 1997) and acts on two membrane-bound receptors (AT1
and AT2). Recent studies have revealed that ANGII also
participates in other physiologic processes including cell growth,
cell differentiation, and receptor-mediated apoptosis (Stoll et al,
1995; Escobar et al, 2004). AT1 is present in all tissues, whereas
AT2 is highly expressed in pathologic conditions such as heart
failure and myocardial hypertrophy (Nahmias and Strosberg, 1995;
Dzau et al, 2001; Touyz and Berry, 2002). Some reports indicate
that ANGII induces neovascularisation (Fernandez et al, 1985; Le
Noble et al, 1991; Andrade et al, 1996) due to the upregulation of
growth factors such as PDGF (Khachigian et al, 2000; Cook et al,
2002), transforming growth factor-b (Kagami et al, 1994; Ohta
et al, 1994; Hamaguchi et al, 1999; Weigert et al, 2002), insulin-like
growth factor-1 (Brink et al, 1999; Haddad et al, 2003), basic
fibroblast growth factor (Peng et al, 2001), VEGF (Otani et al, 1998;
Tamarat et al, 2002), and angiopoietin 2 (Otani et al, 2001).
A local brain RAAS loop has been described to play a role in
hormone production regulation (Ganong, 1984, 1995). Regarding
this, glial cells present AT1 and AT2 ANG receptor-like
immunoreactivity (Fogarty and Matute, 2001). Some studies have
shown that RAAS is expressed by high-grade human astrocytomas,
and is able to synthesise rennin, in contrast to low-grade reactive
astrocytomas which lack RAAS, thus indicating a possible
relationship between endogenous intratumoral rennin and angio-
genesis (Ariza et al, 1988; Juillerat-Jeanneret et al, 2004). In
previous reports, the presence of AT1 was documented in rat
astrocytoma cells (Fogarty et al, 2002). Our group has also shown
that selective blockage of AT1 inhibits tumour growth, cell
proliferation, and angiogenesis by inducing apoptosis in C6 rat
malignant glioma (Arrieta et al, 2005), suggesting that AT1 plays a
significant role in tumour angiogenesis and growth. In this study,
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in the prognosis of patients with astrocytomas.
PATIENTS AND METHODS
Experimental design and patients
With the previous approval of the Institutional Scientific and
Bioethics Committees, we conducted a prospective study at the
Instituto Nacional de Neurologia y Neurocirugia (INNN) of
Mexico. Tumoral tissue of 133 patients with astrocytoma who
underwent surgery from 1997 to 2002 was studied. Patients who
had previously received chemotherapy or radiotherapy were not
included. Patients with low-grade tumours underwent surgical
treatment, whereas those with high-grade tumours were treated by
surgery, radiotherapy, and adjuvant chemotherapy. Patients who
showed disease progression during radiotherapy were excluded.
All patients included in this study were treated in a homogeneous
way. Four samples of non-neoplastic human brain tissue obtained
by surgery for epilepsy were used as controls. Tissue was frozen in
liquid nitrogen and maintained at  701C until AT1 and AT2
determinations were performed.
Angiotensin II AT1 and -2 receptors
Ribonucleic acid (RNA) from tumour samples was obtained using
TRIzol Reagent (Invitrogen, Carlsbad, CA, USA). To minimise the
risk of contaminating DNA, total RNAs were digested with 10U of
DNase I (Boehringer Mannheim, Lewes, UK) for 15min at 371C.
One microgram of total RNA was used for reverse transcription,
which was performed with an RNA PCR Kit (Applied Biosystems,
Branchburg, NJ, USA) following the manufacturer’s instructions.
For ANGII receptor detection, the following primers were used:
sense AT1 50-TTGCAGAGTGGGTGACAGAG-30; antisense AT1
50-TAGCTGAGCTTGCAGAA-30 -30 (393 base pairs (bp)); sense
AT2 50-TTATGGCTTTCCCACCTGAG-30 and reverse AT2
50-GTTGGTGAATCCCAAGAGSGA-30 (342bp); in a total reaction
volume of 20mL. The polymerase chain reaction (PCR) conditions
were: 941C for 5min, followed by 27 cycles at 941C for 30s, 601C
for 30s, and 721C for 60s. The expression of the GAPDH gene
was analysed as a control for the amount and integrity
of the mRNA using the following primers: sense 50-GAAGGTG
AAGGTCGGAGTC-30 antisense 50-CAAGATGGTGATGGGATTTC-30
(226bp). PCR conditions were: 941C for 5min, followed by 27
cycles at 941C for 30s, 551C for 30s, and 721C for 30s.
Immunohistochemistry for AT1 and AT2 receptors
Histological analysis was made in 5-mm tissue sections that were
mounted onto silanised slides. After they were deparaffinised and
rehydrated, antigen was retrieved with 10mM sodium citrate
solution (pH 6.0) preheated at 801C in a water bath, maintaining
this temperature, and keeping sections in this solution for 20min.
After allowing the sections to cool to room temperature, the slides
were rinsed in phosphate-buffered saline (PBS) (pH 7.4).
Endogenous peroxidase activity was quenched by incubation of
the tissue samples for 10min in 3% hydrogen peroxide. Tissue
samples were rinsed gently with PBS and incubated with 1%
bovine serum album (BSA) for 10min. BSA excess was eliminated
and the primary antibodies were incubated for 30min at room
temperature in a moisture chamber.
Dilution of the primary antibodies against AT1 (Rabbit
polyclonal IgG antibody, Santa Cruz Biotechnology Inc.) was
1:300 in BSA 1% in PBS. The polyclonal antirabbit AT1 receptor
antibody (306, catalogue SC579) is specific for AT1 and is mouse,
rat, and human reactive; it does not show cross-reactivity with AT2
(Lu et al, 1998; Ino et al, 2003, 2006), and AT-2 (Goat polyclonal
IgG Santa Cruz Biotechnology Inc.) was 1:300 in BSA 1% in PBS.
One tissue section was used for each antibody. After washing with
PBS, binding of primary antibodies was induced by incubation for
20min with labelled streptavidin biotin System Link (LSAB)
(DAKO Corporation; Carpinteria, CA, USA) and LSABþ HRP
(Streptavidin HRP Kit, DAKO Corporation). The slides were rinsed
with PBS and exposed to the diaminobenzidine chromogen for
5min. After washing with PBS and counter-staining with
haematoxylin, the slides were dehydrated by means of graduated
alcohols and xylol, and mounted with Poly-mount (Polysciences
Inc., Warrington, PA, USA). The slides were observed by light
microscopy. Ten high-power fields (40 ) were analysed in each
specimen. Samples that showed absence of immunoreactivity were
considered negative and those with some percentage of immuno-
reactivity were considered positive. The percentage of AT-positive
tumour cells was estimated and graded into one of three
categories: 1¼low (o35% of positive cells), 2¼intermediate
(35–75% positive cells), or 3¼high (475% positive cells) (Takeda
and Kondo, 2001). Observations were made by a pathologist in a
blinded manner.
Determination of vascular density, mitotic, and cell
proliferation indexes
Mitotic and cell proliferation indexes as well as vascular density
were determined by IHC as previously described (Arrieta et al,
2002). We analysed only 30 tumours owing to insufficient biopsy
material. Briefly, a small tissue sample was fixed in 10% formalin,
and 5-mm slices were obtained. Standard haematoxylin-eosin stain
was used for histological confirmation of diagnosis. Additional
samples were used for IHC with the avidin–biotin–peroxidase
complex, and were counterstained with haematoxylin. Samples
were incubated for 45min at room temperature either with rabbit
antihuman factor VIII-related antigen (DAKO Corporation) as
marker for vascular endothelial cells, or with mouse antiprolifera-
tion cell nuclear antigen (PCNA; DAKO corporation) as marker for
cellular synthesis phase. A pathologist (DR) counted the number of
capillaries positive for factor VIII and the number of cell nuclei
positive for PCNA per microscopic field at  40 magnification in
10 different fields, in a blinded manner.
Statistical analysis
For descriptive purposes, continuous variables were summarised
as arithmetic means, medians, and standard errors (s.e.),
categorical variables as proportions with 95% confidence intervals
(95% CI). Inferential comparisons were performed by Student’s
t- or Mann–Whitney U-tests according to distribution of the data
(normal and non-normal) as determined by the Kolmogorov–
Smirnov test. w
2 or Fisher’s exact test was used to assess
significance between categorical variables. Statistical significance
was determined as Po0.05 with a two-sided test. Statistically
significant and borderline significant variables (Po0.1) were
included in the multivariate logistic regression analysis. Overall
survival time was measured from day of surgery to date of death of
the patient and was analysed with the Kaplan–Meier technique,
whereas comparisons among subgroups were performed with the
log-rank test. For survival curves analysis, all variables were
dichotomised. Adjustment for potential confounders was made by
multivariate regression analysis. SPSS software package version 10
(SPSS Inc., Chicago, IL, USA) was employed to analyse the data.
RESULTS
Patient characteristics and histopathologic diagnosis
Of 133 tumours, low-grade astrocytomas comprised 28% (14%
grade I, and 14% grade II), whereas 72% were high-grade
astrocytomas (17% grade III, and 55% grade IV). Median age of
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sthe patients was 47±1.6 years and mean follow-up time was
9.4±2.2 months (range: 0.1–111 months). Performance status
score (ECOG) was 1 in 29%, 2 in 26%, and 3 in 45% of patients.
Expression of AT1 and AT2 receptors
Angiotensin II receptors expression was analysed by reverse
transcriptase (RT)–PCR in 133 tumours and analysed by IHC in
only 112 because of insufficient tissue samples. AT1/AT2 was not
detected in sections of human brain tissues obtained by surgery for
epilepsy (data not shown). The expression of both receptors was
detected in high-grade astrocytomas (Figure 1B and C). IHC
showed a cytoplasmatic as well as discrete membrane and nuclear
localisation of AT1 (Figure 1B). Fifty-two per cent were positive for
AT1 (95% CI, 43.3–60.4), whereas 44% (95% CI, 35–52) were
positive for AT2 by both methods. There were no tumours
displaying high-intensity staining (475% of cells). There was a
significant correlation (0.73; 95% CI 0.65–0.81; Po0.001) between
the presence of AT1 and AT2 (Po0.001), demonstrating that
45% of tumours expressed both receptors. Moreover, AT1/AT2
expression was detected by RT–PCR (Figure 2). All cases showed
expression of GAPDH. Three representative cases are shown in
Figure 2. Correlation between both methods was 0.93 (95% CI
0.88–0.97; Po0.001). There were no samples with negative
RT–PCR and positive IHC results.
AT1 expression and its clinicopathologic correlation
Table 1 shows the correlation between AT1 expression obtained
by both RT–PCR and IHC according to malignancy grade. The
expression of AT1 was found more frequently in high-grade
tumours (grades 3 and 4) when compared with low-grade tumours
(67 vs 10%, respectively; Po0.0001). Other associated factors with
AT1 expression included: age 447 years (67 vs 43%; P¼0.019)
and poor performance status (65 vs 39%; P¼0.03). In multivariate
analysis, the only significant factors associated with the presence of
AT1 were age (Hazard’s ratio (HR) 3.2 (95% CI, 1.04–10.2);
P¼0.04) and histological grade (HR 13.4 (95% CI, 3.2–55);
Po0.0001). AT1-positive tumours showed higher mitotic index
(3.8±0.1 vs 2.8±0.1; Po0.001), higher proliferation index
(66.8±0.54 vs 51.6±2.3; Po0.001), and higher vascular density
(16±0.4 vs 13.6±0.5; Po0.002) when compared to AT1-negative
tumours. There was no correlation between IHC-staining intensity
and grade of malignancy.
AT2 expression and its clinicopathologic correlation
Table 1 shows the correlation of AT2 expression – obtained by
both RT–PCR and IHC – and grade of malignancy. High-grade
tumours had a greater expression of AT2 than low-grade tumours
(53 vs 17%, respectively; P¼0.001). An additional associated factor
was poor functional status (56 vs 30%; P¼0.04). In the multi-
variate analysis, only the grade of malignancy was associated with
the presence of AT2 (HR 3.4; 95% CI, 1.08–10.86; P¼0.036).
Tumours that expressed this receptor showed a higher mitotic
index (3.95±0.17 vs 3.15±0.1; P¼0.001), higher proliferation
index (66.4±0.6 vs 58.1±2.4; P¼0.004), and higher vascular
density (16.7±0.39 vs 14.06±0.4; Po0.001) when compared to
AT2-negative tumours. There was no correlation between the
intensity of IHC staining and grade of malignancy.
AB
C
Figure 1 Immunoreactivity for AT receptors in high-grade astrocytoma: (A) negative, (B) AT1 positive, and (C) AT2 positive.
1234
AT1 393 bp
AT2 342 bp
GAPDH 226 bp
Figure 2 Determination of AT1 and AT2 mRNAs by RT–PCR
performed in three high-grade astrocytoma surgical samples; lane 1
corresponds to positive control; lanes 2, 3, and 4 correspond to different
surgical samples.
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sSurvival of patients with malignant astrocytomas
Median overall survival for all patients was 9.7±2.0 months.
Table 2 shows survival-associated factors in both the univariate
and the multivariate analyses. Survival-associated factors in the
univariate analysis were histological grade (I/II vs III/IV;
Po0.001), age (p47 vs 447 years; Po0.001), performance status
(ECOG p1 vs X2; Po0.001), and mitotic index (p3.3 vs 43.3;
P¼0.007), predictive factors previously reported. Interestingly,
patients with AT1-positive tumours (IHC- and RT–PCR positive)
showed a lower survival rate (3.3±1.3 vs 34±14.3; Po0.0001). The
presence of AT2 was also associated with a decrease in overall
survival (3.3±1.6 vs 12.8±3; P¼0.006). There was no association
between the intensity of IHC staining for both AT1 and AT2 and
survival. In the multivariate analysis, statistically significant
factors for poor prognosis were: diagnosis of high-grade astro-
cytoma (P¼0.05), poor performance status (Po0.001), high
mitotic index (P¼0.03), and AT1 expression (P¼0.01, (Figure 3)).
DISCUSSION
Previous reports have described the expression of both RAAS and
AT1 in normal brain tissue as well as their possible participation in
cerebral vascular regulation (Ganong, 1984). Likewise, the
presence of AT1 and AT2 in C6 glioma cells has been described,
showing that their blockage can inhibit tumoral growth and
angiogenesis (Rivera et al, 2001; Fogarty et al, 2002; Arrieta et al,
2005). Recent reports describe the local expression of many
components of RAAS in several human neoplasms, among these
human GM (Deshayes and Nahmias, 2005). We show the presence
of AT1 and AT2 in 52 and 44% of human astrocytomas,
respectively; therefore, it will be important to evaluate the cellular
function of this type of molecules in the near future. Although
there was a significant correlation (0.93) between both methods,
four tumours were positive for the expression of AT receptors by
RT–RCR but were negative by IHC. This is probably due to the
higher sensibility of the former method or because the tumour is
expressing the AT-receptors’ mRNA, but not the protein at the
membrane level. The IHC shows expression of AT1 and AT2 in
tumoral cells, discarding the fact that the results obtained by
RT–PCR are due to the presence of AT1 and AT2 in vascular brain
tissue. We observed the localisation of AT1 receptor within the
nucleus, membrane, and cytoplasm. These observations concur
with previous reports in which nuclear ANGII receptors have been
demonstrated in brain neurons, hepatocytes, and human embryo-
nic kidney (HEK-293T) (Booz et al, 1992; Lu et al, 1998; Lee et al,
2004), thus suggesting AT2-induced nuclear sequestration of the
AT1 receptor.
Expression of AT1 and AT2, as well as other RAAS components
in cells from human astrocytomas, was variable, possibly related to
clonal heterogeneity (Juillerat-Jeanneret et al, 2004). However, we
found that the presence of AT1 and AT2 was associated with the
grade of malignancy. Similar findings have been reported with the
Table 1 Proportion of negative and positive tumours to AT1 and AT2
expression by RT–PCR and IHC according to malignancy grade
AT1* AT2**
Tumour
grade
Negative
(%)
Positive
(%)
Negative
(%)
Positive
(%)
Grade 1 12 (86) 2 (14) 12 (86) 2 (14)
Grade 2 14 (93) 1 (7) 12 (80) 3 (20)
Grade 3 5 (28) 13 (72) 7 (39) 11 (61)
Grade 4 21 (34) 40 (66) 30 (49) 31 (51)
Total 52 (48) 56 (52) 61 (56.5) 47(43.5)
Abbreviation: RT–PCR¼reverse transcriptase–polymerase chain reaction.
*Po0.001, **P¼0.008.
Table 2 Survival associated factors
Univariate analysis Multivariate analysis
Factor Months±s.e. P-value HR (CI 95%) P-value
Age (years)
p47 24.5±9.11 o0.001 1.79 (1.035–3.103) 0.037
447 5.5±1.3
Gender
Male 12.6±1.9 0.262
Female 5.4±2.6
ECOG
p1 61.4±28.2 o0.001 1.46 (1.06–2.025) 0.021
X2 5.5±1.6
Grade
I/II 42.6±22.1 o0.001 1.2 (1.0–1.5) 0.05
III/IV 7.03±1.51
MI
p3.3 33.9±10.8 0.007 5.6 (1.181–26.7) 0.03
43.3 5.4±1.52
IPCNA
p65 14.9±27 0.14
465 6.6±4
VD
p15.9 12.5±0.7 0.48
415.9 9.2±5
AT1
Positive 33.9±14.1 o0.001 2.056 (1.189–3.5) 0.01
Negative 3.3±1.4
AT2
Positive 12.8±3.01 0.006 0.725 (0.5–1.64) 0.7
Negative 3.3±1.58
Abbreviations: CI¼ confidence interval; HR¼Hazard’s ratio; IPCNA¼index of
proliferation cell nuclear antigen; MI¼mitotic index; s.e.¼standard error; VD¼
vascular density.
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Figure 3 Overall survival and AT1 expression.
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sexpression of ANGII in normal brain tissue, in low-grade tumours,
and in high-grade tumours (Juillerat-Jeanneret et al, 2004).
The presence of ANGII receptors in AA and GM and their
correlation with mitotic and proliferation indexes, as well as with
vascular density, suggest that both AT1 and AT2 play a role in the
regulation of several tissular processes such as angiogenesis, cell
proliferation, invasiveness, and apoptosis (Escobar et al, 2004),
either through the stimulation or the inhibition of RAAS
components locally synthesised by the tumour (Juillerat-Jeanneret
et al, 2004). In this matter, we found that there is co-expression of
AT1 and AT2 in malignant tumours, suggesting a possible relation
between both receptors. It is known that the stimulation of AT2
can inhibit AT1 activation pathways, leading to growth inhibition.
The presence of both receptors in the same tumour suggests that
selective blockage of one receptor could increase the effect of the
other (Arrieta et al, 2005). It is possible that AT1 inhibition
produces disequilibrium in the AT1/AT2 stimulation, which in
turn favours AT2 stimulation, thus opening the possibility of the
pathway leading mainly to apoptosis. There are other endogenous
peptide hormones of the RAAS, such as AT1-5 and AT1-7, which
could regulate proliferation processes in neoplastic cells; it has
been demonstrated that AT1-7 inhibits proliferation and induces
apoptosis of human lung cancer cells through its receptor MAS
(Gallagher and Tallant 2004). Further studies should be performed
to determine the presence of these peptides and their receptors in
human gliomas to establish their influence over their cellular
proliferation and behaviour.
We also found an independent association between AT1
expression and vascular density. Previous reports have shown
that the stimulation of this receptor augments VEGF expression in
various tumoral and non-tumoral tissues and that its blockage
inhibits VEGF expression in gliomas and other tissues (Chua et al,
1998; Tamarat et al, 2002; Arrieta et al, 2005; Imai et al, 2007). In
addition, AT1 selective blockage inhibits cell proliferation and
neovascularisation in experimental C6 rat glioma (Rivera et al,
2001; Arrieta et al, 2005), which is known to express AT1 (Rivera
et al, 2001; Fogarty et al, 2002). Similarly, experimental AT1
blockage has shown growth inhibition in other neoplasms such as
melanoma (Egami et al, 2003), lung carcinoma (Fujita et al, 2005),
prostate adenocarcinoma (Uemura et al, 2005), renal cancer
(Miyajima et al, 2002), and pancreatic cancer (Fujimoto et al,
2001). Although other growth factors have been involved in
ANGII-induced tumoral angiogenesis, it appears that VEGF plays a
crucial role in this matter. It has been shown that when murine
Lewis lung carcinoma (LLC) cells – which express AT1 – are
implanted subcutaneously into wild-type mice, they develop
tumours that exhibit intense angiogenesis and induction of VEGF.
However, when LLC cells are implanted in AT1a gene-deficient
(AT1a / ) mice, tumour growth and tumour-associated angio-
genesis are reduced, with reduced expression of VEGF (Imai et al,
2007). Coincidentally, VEGF is rather important in GM patho-
physiology: a critical difference between a low- and high-grade
astrocytoma is the increase in VEGF-induced vascular density
(Yao et al, 2001). This growth factor is essential in the malignant
progression of gliomas (Godard et al, 2003; Karcher et al, 2006).
The fact that AT1 is present in high-grade astrocytomas and in
patients 447 years of age suggests that AT1 and AT2 could be
associated with the progression of malignancy in secondary
malignant astrocytomas.
In our study, we found that histological grade, ECOG
performance status, and age were factors associated with survival
in the multivariate analysis. These factors have previously shown
their prognostic importance in patients with high-grade astro-
cytomas treated with radiotherapy and adjuvant chemotherapy,
and have been included in the recursive partitioning analysis
developed to compare the survival categories to obtain homo-
geneous subsets of patients. Some studies have reported an
interaction between age and genetic alterations (such as TP53
mutations and EGFR amplification) in GM, suggesting that
tumorigenic pathways to GM vary according to the patient’s age
(Batchelor et al, 2004). The complex interactions between age and
genetic alterations could explain the association between the
former and the AT1 expression. Furthermore, given the age
dependency of these genetic effects, it will be intriguing to analyse
the genetic expression patterns in younger and older patients to
ascertain AT1 and AT2 genetic pathways in astrocytomas.
This is the first report documenting the association between the
presence of AT1/AT2 and poor prognosis in patients with high-
grade astrocytoma. This study demonstrates that AT1 expression is
an independent survival-related factor, suggesting that this
receptor plays an essential role in the pathophysiology of high-
grade astrocytomas.
A limitation of our study is the difference in the survival rates
compared to those reported in the literature. Patients with low-
grade astrocytoma have a survival average of 7–10 years in
contrast to our population, which showed a survival median of 3.4
years. In the same manner, patients with high-grade astrocytomas,
treated with chemotherapy and concomitant radiotherapy and
posteriorly with adjuvant temozolamide, have a median survival of
12.1–14.6 months (Mirimanoff et al, 2006), in contrast to the
patients in our study who displayed a median survival of 7 months.
These disparities could be accounted for by: (1) the nature of the
studies (observational vs controlled studies), and (2) differences in
the treatment schema. All patients with high-grade astrocytomas
in our study were treated with radiotherapy and adjuvant
chemotherapy based on carmustine.
In conclusion, our study demonstrates that AT1 and AT2 are
strongly expressed in high-grade astrocytomas, and it is the first
report that shows an association with poor prognosis. These
preliminary results suggest that these receptors are attractive
therapeutic targets.
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